Genmab — August 2019
-
Data from the Phase II GRIFFIN study (MMY2004) and data from the Phase II PLEIADES (MMY2040) study were both accepted for presentation during oral sessions at the conference. The abstracts are available on the conference website and may be accessed via http://imw2019boston.org.
-
-
Pleiades konklusion: Conclusions: DARA SC in combination
with SoC regimens demonstrated comparable
clinical activity and safety to corresponding DARA
IV regimens, with considerably lower IRR rates and
substantially shorter durations of administration. -
Griffin konklusion: Conclusions: D-RVd induces higher
response rates and greater depth of response,
including sCR and MRD negativity, than RVd. The
overall safety profile of D-RVd is consistent with
previous reports of DARA and RVd, and stem cell
mobilization and ASCT are feasible with D-RVd. -
-
Laksen og sol har hevet mig flot igennem i de seneste par år, hvor Genmab og Novo har været har været "døde penge". I år har alle aktierne steget i skøn forening.
-
Har købt mindre beholdninger op i gasrederier i 2018 og 2019. De er steget med 50-110%. Bliver der ro på handelskrigen kører de stærkt videre i tredje og fjerde kvartal.
-
Enig.
-
For alt og alle.
-
Godnat herfra.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind